444 related articles for article (PubMed ID: 15472421)
1. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores.
Atasoy HT; Nuyan O; Tunc T; Yorubulut M; Unal AE; Inan LE
Neurol India; 2004 Sep; 52(3):332-7. PubMed ID: 15472421
[TBL] [Abstract][Full Text] [Related]
2. [Magnetic resonance imaging in Parkinson's disease--the evaluation of the width of pars compacta on T2 weighted image].
Moriwaka F; Tashiro K; Itoh K; Hamada T; Miyasaka K
Rinsho Shinkeigaku; 1992 Jan; 32(1):8-12. PubMed ID: 1628441
[TBL] [Abstract][Full Text] [Related]
3. [MRI in Parkinson's disease and vascular parkinsonism--study on the lesion of substantia nigra].
Aotsuka A; Shinotoh H; Hirayama K; Ikehira H; Fukuda H
Rinsho Shinkeigaku; 1991 Jun; 31(6):619-24. PubMed ID: 1934776
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease.
Geng DY; Li YX; Zee CS
Neurosurgery; 2006 Feb; 58(2):256-62; discussion 256-62. PubMed ID: 16462479
[TBL] [Abstract][Full Text] [Related]
5. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease.
O'Neill J; Schuff N; Marks WJ; Feiwell R; Aminoff MJ; Weiner MW
Mov Disord; 2002 Sep; 17(5):917-27. PubMed ID: 12360540
[TBL] [Abstract][Full Text] [Related]
6. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
[TBL] [Abstract][Full Text] [Related]
7. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
Langley J; Huddleston DE; Sedlacik J; Boelmans K; Hu XP
Mov Disord; 2017 Mar; 32(3):441-449. PubMed ID: 28004859
[TBL] [Abstract][Full Text] [Related]
10. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
[TBL] [Abstract][Full Text] [Related]
11. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
Wang C; Fan G; Xu K; Wang S
Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
[TBL] [Abstract][Full Text] [Related]
12. MRI assessment of basal ganglia iron deposition in Parkinson's disease.
Wallis LI; Paley MN; Graham JM; Grünewald RA; Wignall EL; Joy HM; Griffiths PD
J Magn Reson Imaging; 2008 Nov; 28(5):1061-7. PubMed ID: 18972346
[TBL] [Abstract][Full Text] [Related]
13. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study.
Zhang J; Zhang Y; Wang J; Cai P; Luo C; Qian Z; Dai Y; Feng H
Brain Res; 2010 May; 1330():124-30. PubMed ID: 20303339
[TBL] [Abstract][Full Text] [Related]
14. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status.
Martin WR; Wieler M; Gee M
Neurology; 2008 Apr; 70(16 Pt 2):1411-7. PubMed ID: 18172063
[TBL] [Abstract][Full Text] [Related]
15. MRI atrophy parameters related to cognitive and motor impairment in Parkinson's disease.
Alegret M; Junqué C; Pueyo R; Valldeoriola F; Vendrell P; Tolosa E; Mercader JM
Neurologia; 2001 Feb; 16(2):63-9. PubMed ID: 11257931
[TBL] [Abstract][Full Text] [Related]
16. [Magnetic resonance imaging in multiple system atrophy].
Aotsuka A; Shinotoh H; Hirayama K; Ikehira H; Hashimoto T
Rinsho Shinkeigaku; 1992 Aug; 32(8):815-21. PubMed ID: 1490308
[TBL] [Abstract][Full Text] [Related]
17. [Importance of magnetic resonance in Parkinson disease. An analytic study of the pars compacta].
Maurício JC; Coelho H; Sá J; Martins A
Acta Med Port; 1990; 3(2):85-8. PubMed ID: 2349893
[TBL] [Abstract][Full Text] [Related]
18. Magnetization transfer ratio in early period of Parkinson disease.
Anik Y; Iseri P; Demirci A; Komsuoglu S; Inan N
Acad Radiol; 2007 Feb; 14(2):189-92. PubMed ID: 17236991
[TBL] [Abstract][Full Text] [Related]
19. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
[TBL] [Abstract][Full Text] [Related]
20. Parkinson's disease related signal change in the nigrosomes 1-5 and the substantia nigra using T2* weighted 7T MRI.
Schwarz ST; Mougin O; Xing Y; Blazejewska A; Bajaj N; Auer DP; Gowland P
Neuroimage Clin; 2018; 19():683-689. PubMed ID: 29872633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
